Literature DB >> 11559806

Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.

J E Blaney1, D H Johnson, C Y Firestone, C T Hanson, B R Murphy, S S Whitehead.   

Abstract

A recombinant live attenuated dengue virus type 4 (DEN4) vaccine candidate, 2ADelta30, was found previously to be generally well tolerated in humans, but a rash and an elevation of liver enzymes in the serum occurred in some vaccinees. 2ADelta30, a non-temperature-sensitive (non-ts) virus, contains a 30-nucleotide deletion (Delta30) in the 3' untranslated region (UTR) of the viral genome. In the present study, chemical mutagenesis of DEN4 was utilized to generate attenuating mutations which may be useful in further attenuation of the 2ADelta30 candidate vaccine. Wild-type DEN4 2A virus was grown in Vero cells in the presence of 5-fluorouracil, and a panel of 1,248 clones were isolated. Twenty ts mutant viruses were identified that were ts in both simian Vero and human liver HuH-7 cells (n = 13) or only in HuH-7 cells (n = 7). Each of the 20 ts mutant viruses possessed an attenuation phenotype, as indicated by restricted replication in the brains of 7-day-old mice. The complete nucleotide sequence of the 20 ts mutant viruses identified nucleotide substitutions in structural and nonstructural genes as well as in the 5' and 3' UTRs, with more than one change occurring, in general, per mutant virus. A ts mutation in the NS3 protein (nucleotide position 4995) was introduced into a recombinant DEN4 virus possessing the Delta30 deletion, thereby creating rDEN4Delta30-4995, a recombinant virus which is ts and more attenuated than rDEN4Delta30 virus in the brains of mice. We are assembling a menu of attenuating mutations that should be useful in generating satisfactorily attenuated recombinant dengue vaccine viruses and in increasing our understanding of the pathogenesis of dengue virus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11559806      PMCID: PMC114545          DOI: 10.1128/JVI.75.20.9731-9740.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Research on dengue during World War II.

Authors:  A B SABIN
Journal:  Am J Trop Med Hyg       Date:  1952-01       Impact factor: 2.345

2.  Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses.

Authors:  J F Bazan; R J Fletterick
Journal:  Virology       Date:  1989-08       Impact factor: 3.616

3.  A prospective study of dengue infections in Bangkok.

Authors:  D S Burke; A Nisalak; D E Johnson; R M Scott
Journal:  Am J Trop Med Hyg       Date:  1988-01       Impact factor: 2.345

4.  Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14.

Authors:  H Ni; G J Chang; H Xie; D W Trent; A D Barrett
Journal:  J Gen Virol       Date:  1995-02       Impact factor: 3.891

5.  Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis.

Authors:  A D Jennings; C A Gibson; B R Miller; J H Mathews; C J Mitchell; J T Roehrig; D J Wood; F Taffs; B K Sil; S N Whitby
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

6.  A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans.

Authors:  R Edelman; C O Tacket; S S Wasserman; D W Vaughn; K H Eckels; D R Dubois; P L Summers; C H Hoke
Journal:  J Infect Dis       Date:  1994-12       Impact factor: 5.226

7.  Dengue-2 virus infection of human mononuclear cell lines and establishment of persistent infections.

Authors:  I Kurane; U Kontny; J Janus; F A Ennis
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

8.  Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine.

Authors:  E Wang; K D Ryman; A D Jennings; D J Wood; F Taffs; P D Minor; P G Sanders; A D Barrett
Journal:  J Gen Virol       Date:  1995-11       Impact factor: 3.891

9.  Liver biochemical tests and dengue fever.

Authors:  C H Kuo; D I Tai; C S Chang-Chien; C K Lan; S S Chiou; Y F Liaw
Journal:  Am J Trop Med Hyg       Date:  1992-09       Impact factor: 2.345

10.  Comparison of a dengue-2 virus and its candidate vaccine derivative: sequence relationships with the flaviviruses and other viruses.

Authors:  J Blok; S M McWilliam; H C Butler; A J Gibbs; G Weiller; B L Herring; A C Hemsley; J G Aaskov; S Yoksan; N Bhamarapravati
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

View more
  30 in total

1.  Replacement of the 3' untranslated variable region of mosquito-borne dengue virus with that of tick-borne Langat virus does not alter vector specificity.

Authors:  Ebenezer Tumban; Dana N Mitzel; Nyree E Maes; Christopher T Hanson; Stephen S Whitehead; Kathryn A Hanley
Journal:  J Gen Virol       Date:  2011-01-07       Impact factor: 3.891

Review 2.  Flavivirus RNA synthesis in vitro.

Authors:  Radhakrishnan Padmanabhan; Ratree Takhampunya; Tadahisa Teramoto; Kyung H Choi
Journal:  Methods       Date:  2015-08-10       Impact factor: 3.608

3.  A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice.

Authors:  Alexander A Rumyantsev; Brian R Murphy; Alexander G Pletnev
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes.

Authors:  Kathryn A Hanley; Jay J Lee; Joseph E Blaney; Brian R Murphy; Stephen S Whitehead
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.

Authors:  Jorge E Osorio; Joseph N Brewoo; Shawn J Silengo; John Arguello; Ioana R Moldovan; Magdalena Tary-Lehmann; Tim D Powell; Jill A Livengood; Richard M Kinney; Claire Y-H Huang; Dan T Stinchcomb
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

6.  The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3' non-coding region of the genome.

Authors:  Amber R Engel; Alexander A Rumyantsev; Olga A Maximova; James M Speicher; Brian Heiss; Brian R Murphy; Alexander G Pletnev
Journal:  Virology       Date:  2010-07-01       Impact factor: 3.616

7.  West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy.

Authors:  Alexander G Pletnev; Robert Putnak; Jim Speicher; Eric J Wagar; David W Vaughn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

8.  Replacement of conserved or variable sequences of the mosquito-borne dengue virus 3' UTR with homologous sequences from Modoc virus does not change infectivity for mosquitoes.

Authors:  Ebenezer Tumban; Nyree E Maes; Erin E Schirtzinger; Katherine I Young; Christopher T Hanson; Stephen S Whitehead; Kathryn A Hanley
Journal:  J Gen Virol       Date:  2012-12-19       Impact factor: 3.891

9.  A single point mutation in nonstructural protein NS2 of bovine viral diarrhea virus results in temperature-sensitive attenuation of viral cytopathogenicity.

Authors:  Alexander Pankraz; Simone Preis; Heinz-Jürgen Thiel; Andreas Gallei; Paul Becher
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

10.  Identification of genetic determinants of a tick-borne flavivirus associated with host-specific adaptation and pathogenicity.

Authors:  Dana N Mitzel; Sonja M Best; Max F Masnick; Stephen F Porcella; James B Wolfinbarger; Marshall E Bloom
Journal:  Virology       Date:  2008-09-26       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.